20 April 2015
Dortmund, Germany, 20 April, 2015 – The Charcot-Marie-Tooth Association (CMTA) announced today that is has entered into a collaboration with Affectis Pharmaceuticals AG. The goal of the collaboration will be to evaluate the pharmacology of small molecule antagonists of the P2X7 ligand-gated ion channel that are being jointly developed by Affectis and the LDC. The CMTA consortium will evaluate the efficacy of advanced Affectis compounds in neurological and behavioral models of CMT1A...
Download File (204KB):
CMTA-Affectis Collaboration Announcement